This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EPZM Epizyme (EPZM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Epizyme Stock (NASDAQ:EPZM) 30 days 90 days 365 days Advanced Chart Remove Ads Get Epizyme alerts:Sign Up Key Stats Today's Range$1.47▼$1.4750-Day Range$1.47▼$1.5252-Week Range$0.41▼$5.80Volume7,960 shsAverage Volume3.23 million shsMarket Capitalization$247.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEpizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Read More… Remove Ads Receive EPZM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Epizyme and its competitors with MarketBeat's FREE daily newsletter. Email Address EPZM Stock News Headlinesbluebird bio Inc BLUENovember 1, 2023 | morningstar.comCelgene, Jounce Therapeutics in Early Cancer Immunotherapy Development PactMarch 22, 2023 | thestreet.comThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR! He says these 5 stocks are trading for less than $2 right now… But they could soon SOAR in Trump’s first 100 days.April 4, 2025 | Timothy Sykes (Ad)Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal - NasdaqAugust 12, 2022 | nasdaq.comForm SC 14D9/A Epizyme, Inc. Filed by: Epizyme, Inc. - StreetInsider.comAugust 12, 2022 | streetinsider.comThe past five years for Epizyme (NASDAQ:EPZM) investors has not been profitableAugust 10, 2022 | finance.yahoo.comEpizyme: Q2 Earnings Insights - BenzingaAugust 9, 2022 | benzinga.comEpizyme Reports Second Quarter 2022 Financial Results and Provides Business Update - Business WireAugust 9, 2022 | businesswire.comSee More Headlines EPZM Stock Analysis - Frequently Asked Questions How were Epizyme's earnings last quarter? Epizyme, Inc. (NASDAQ:EPZM) issued its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.16. Epizyme's quarterly revenue was up 45.8% compared to the same quarter last year. What other stocks do shareholders of Epizyme own? Based on aggregate information from My MarketBeat watchlists, some other companies that Epizyme investors own include Novavax (NVAX), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), Pfizer (PFE), Applied Materials (AMAT) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/09/2021Today4/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EPZM CIK1571498 Webwww.epizyme.com Phone(617) 229-5872Fax617-349-0707Employees250Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-251,120,000.00 Net Margins-391.90% Pretax Margin-391.80% Return on Equity-2,459.33% Return on Assets-69.74% Debt Debt-to-Equity RatioN/A Current Ratio5.35 Quick Ratio5.19 Sales & Book Value Annual Sales$37.43 million Price / Sales6.61 Cash FlowN/A Price / Cash FlowN/A Book Value($0.54) per share Price / Book-2.72Miscellaneous Outstanding Shares168,329,000Free Float128,968,000Market Cap$247.44 million OptionableOptionable Beta-0.41 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:EPZM) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Epizyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Epizyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.